NHS will not fund Kanuma for rare disease LAL-D.
Body unconvinced by clinical data for Venclyxto .
HeartFlow could save NHS England a minimum of around £9.1 million by 2022.
SMC backs drug based on feedback from patients and doctors, after rejection by NICE.
Leukaemia drug latest to move out of Cancer Drugs Fund
Watchdog accused of ignoring stakeholder consensus and call for negotiations
Ibrance too expensive at almost £80,000 per course.
J&J unit awaiting decisions in two more blood cancer uses.
NHS England and NICE are attempting to reduce budget impact of drugs.